PH31266A - Methods of inhibiting weight gain or inducing weight loss. - Google Patents

Methods of inhibiting weight gain or inducing weight loss.

Info

Publication number
PH31266A
PH31266A PH49576A PH49576A PH31266A PH 31266 A PH31266 A PH 31266A PH 49576 A PH49576 A PH 49576A PH 49576 A PH49576 A PH 49576A PH 31266 A PH31266 A PH 31266A
Authority
PH
Philippines
Prior art keywords
methods
inhibiting
inducing
weight loss
weight
Prior art date
Application number
PH49576A
Other languages
English (en)
Inventor
Henry U Bryant
Jeffrey A Dodge
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH31266A publication Critical patent/PH31266A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PH49576A 1993-12-21 1994-12-19 Methods of inhibiting weight gain or inducing weight loss. PH31266A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,291 US5578613A (en) 1993-12-21 1993-12-21 Methods for inhibiting weight gain or inducing weight loss

Publications (1)

Publication Number Publication Date
PH31266A true PH31266A (en) 1998-06-18

Family

ID=22623225

Family Applications (1)

Application Number Title Priority Date Filing Date
PH49576A PH31266A (en) 1993-12-21 1994-12-19 Methods of inhibiting weight gain or inducing weight loss.

Country Status (16)

Country Link
US (2) US5578613A (cs)
EP (1) EP0659423A1 (cs)
JP (1) JPH07196492A (cs)
KR (1) KR950016741A (cs)
CN (1) CN1107707A (cs)
AU (1) AU8154094A (cs)
CA (1) CA2138455A1 (cs)
CZ (1) CZ322294A3 (cs)
HU (1) HUT71342A (cs)
IL (1) IL112044A (cs)
NO (1) NO944923L (cs)
NZ (1) NZ270182A (cs)
PH (1) PH31266A (cs)
RU (1) RU94044357A (cs)
TW (1) TW272126B (cs)
ZA (1) ZA9410090B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5900418A (en) * 1997-02-10 1999-05-04 Synapse Pharmaceuticals International, Inc. Method for treatment of obesity
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
HRP20000862A2 (en) 1998-06-16 2001-10-31 Lilly Co Eli Methods for increasing levels of acetylcholine
CN1250563C (zh) 1999-05-04 2006-04-12 斯特拉坎有限公司 雄激素糖苷及其产生雄性征的活性
EP1789806A2 (en) * 2004-09-13 2007-05-30 Lipomics Technologies, Inc. Metabolite markers for weight management
CA2588087A1 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
HRP20160569T1 (hr) 2007-12-03 2016-07-29 Obe Therapy Biotechnology Boropeptidni inhibitori enteropeptidaze i njihove uporabe u liječenju pretilosti, pretjerane tjelesne težine i/ili bolesti povezane s abnormalnim metabolizmom masti
WO2013102207A1 (en) * 2011-12-30 2013-07-04 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW303299B (cs) * 1993-07-22 1997-04-21 Lilly Co Eli

Also Published As

Publication number Publication date
CN1107707A (zh) 1995-09-06
US5578614A (en) 1996-11-26
CZ322294A3 (en) 1995-09-13
RU94044357A (ru) 1996-10-20
NZ270182A (en) 1996-08-27
HU9403673D0 (en) 1995-02-28
IL112044A (en) 1999-01-26
TW272126B (cs) 1996-03-11
KR950016741A (ko) 1995-07-20
AU8154094A (en) 1995-06-29
JPH07196492A (ja) 1995-08-01
IL112044A0 (en) 1995-03-15
CA2138455A1 (en) 1995-06-22
US5578613A (en) 1996-11-26
ZA9410090B (en) 1996-06-19
HUT71342A (en) 1995-11-28
EP0659423A1 (en) 1995-06-28
NO944923D0 (no) 1994-12-19
NO944923L (no) 1995-06-22

Similar Documents

Publication Publication Date Title
EP0612249A4 (en) Methods of inhibiting restenosis.
PH30895A (en) Detoxification of soil.
EP0623371A3 (de) Ballongegengewicht.
EP0601322A3 (en) Adenosine deaminase inhibitor.
ZA956991B (en) Methods of inhibiting ulcerative mucositis.
EP0614944A3 (de) Intumeszierende Zusammensetzung vom Zwei-Komponenten-Typ.
IL107830A0 (en) Missile
PH31266A (en) Methods of inhibiting weight gain or inducing weight loss.
AU7680891A (en) The method of inhibiting discoloration of produce
PH31326A (en) Methods of inhibiting breast disorders.
EP0605164A3 (en) Checkweigher.
GR3026571T3 (en) Preparation of 2-H-heptafluoropropane.
ZA927463B (en) Transplant protective coating.
ZA943316B (en) Process for the preparation of microballs and microballs thus obtained.
GB9424674D0 (en) Polypeptudes which inhibit NADPH oxidase complex
EP0652284A3 (en) Beer preparation.
EP0649308A4 (en) PREVENTION OF HEMOLYSIS.
HU9403422D0 (en) Methods of inhibiting the effects of amyloidogenic proteins
PL297110A1 (en) Herbicidal sulphonamides, method of obtaining novel sulphonamides and herbicide as such
AU4519293A (en) Soft steel projectile
EP0624089A4 (en) Methods.
GB9316706D0 (en) Divers weight
EP0621277A3 (de) Diarylderivate und deren Verwendung als Pflanzenschutzmittel.
GB9310883D0 (en) Use of trithiadiazephines as biocides
MXPA94001311A (es) Combinaciones de inhibidores retrovirales.